Hematopoietic
stem
cell
transplantation
is
one
of
the
most
intricate
immune
therapies
used
for
patients
with
hematological
diseases
or
disorders.
In
addition
to
inherent
immunosuppression
from
their
primary
condition,
many
these
usually
receive
cytotoxic
chemotherapy,
radiation
therapy,
broad-spectrum
antibiotics,
experience
extended
nutritional
perturbations.
These
factors
collectively
lead
inflammation
and
disruption
gut
microbiota.
Additionally,
about
40–60%
undergoing
fully
HLA-matched
allogeneic
are
expected
develop
acute
graft-versus-host
disease
(aGVHD),
even
prophylactic
measures
such
as
calcineurin
inhibitors,
methotrexate/mycophenolate,
post-transplant
cyclophosphamide
treatment.
Recent
research
has
elucidated
complex
interplay
between
effectors
in
gastrointestinal
tract
microbial
populations
within
a
proinflammatory
peri-transplant
environment,
revealing
its
significant
effect
on
survival
complications
aGVHD.
This
review
will
explore
relationship
dysbiosis
during
mechanisms
that
can
help
clarify
link
microbiota
risk
GVHD,
along
emerging
therapeutic
strategies
aimed
at
addressing
hematopoietic
transplantation.
Frontiers in Cardiovascular Medicine,
Год журнала:
2025,
Номер
12
Опубликована: Фев. 4, 2025
Atrial
cardiomyopathy
is
a
multifaceted
heart
disease
characterized
by
structural
and
functional
abnormalities
of
the
atria
closely
associated
with
atrial
fibrillation
its
complications.
Its
etiology
involves
number
factors,
including
genetic,
infectious,
immunologic,
metabolic
factors.
Recent
research
has
highlighted
critical
role
gut
microbiota
in
pathogenesis
cardiomyopathy,
this
consistent
gut–heart
axis
having
major
implications
for
cardiac
health.
The
aim
work
to
bridge
knowledge
gap
regarding
interactions
between
particular
focus
on
elucidating
mechanisms
which
dysbiosis
may
induce
remodeling
dysfunction.
This
article
provides
an
overview
changes
composition
effects
metabolites.
We
also
discuss
how
diet
exercise
affect
influencing
microbiota,
as
well
possible
future
therapeutic
approaches
targeting
axis.
A
healthy
can
prevent
disease,
but
ecological
lead
variety
symptoms,
induction
disease.
pathophysiological
aspects
impact
structure
function,
strategies
exploring
modulation
treatment
cardiomyopathy.
Finally,
we
fecal
transplantation
oral
probiotics
or
prebiotics.
Our
study
highlights
importance
homeostasis
cardiovascular
health
suggests
that
targeted
interventions
pave
way
innovative
preventive
Biology,
Год журнала:
2025,
Номер
14(3), С. 251 - 251
Опубликована: Фев. 28, 2025
CRC
remains
a
significant
public
health
challenge
due
to
its
high
prevalence
and
mortality
rates.
Emerging
evidence
highlights
the
critical
role
of
gut
microbiota
in
both
pathogenesis
efficacy
treatment
strategies,
including
chemotherapy
immunotherapy.
Dysbiosis,
characterized
by
imbalances
microbial
communities,
has
been
implicated
progression
therapeutic
outcomes.
This
review
examines
intricate
relationship
between
composition
CRC,
emphasizing
potential
for
profiles
serve
as
biomarkers
early
detection
prognosis.
Various
interventions,
such
prebiotics,
probiotics,
postbiotics,
fecal
transplantation,
dietary
modifications,
aim
restore
balance
shift
dysbiosis
toward
eubiosis,
thereby
improving
Additionally,
integration
profiling
into
clinical
practice
could
enhance
diagnostic
capabilities
personalize
advancing
field
oncology.
The
study
intratumoral
offers
new
prognostic
tools
that,
combined
with
artificial
intelligence
algorithms,
predict
responses
assess
risk
adverse
effects.
Given
growing
understanding
microbiome–cancer
axis,
developing
microbiota-oriented
strategies
prevention
holds
promise
patient
care
Microorganisms,
Год журнала:
2025,
Номер
13(3), С. 587 - 587
Опубликована: Март 4, 2025
Fecal
microbiota
transplantation
(FMT)
is
the
most
effective
therapy
for
preventing
recurrent
Clostridioides
difficile
infection
(rCDI).
However,
impact
of
FMT
formulations
and
storage
conditions
on
bacterial
viability,
community
structure,
functionality,
clinical
efficacy
remains
under-investigated.
We
studied
effect
different
viability
(live/dead
staining
cell
sorting),
structure
(16S
rDNA
analysis),
metabolic
functionality
(fermentation)
frozen
lyophilized
formulations.
The
success
rates
rCDI
patients
were
correlated
retrospectively
with
formulations,
durations,
host
factors
using
Edmonton
program
database.
Bacterial
remained
at
10–20%
across
various
was
comparable
to
that
fresh
FMT.
Live
dead
fractions
in
both
preparations
exhibited
distinct
structures.
Storage
but
not
temperatures,
negatively
affected
diversity.
More
short-chain
fatty
acids
found
metabolomic
profiling
vitro
fermentation
products
than
Clinical
537
receiving
a
single
dose
significantly
among
three
longer
durations
advanced
recipient
age
impacted
efficacy.
Together,
our
findings
suggest
should
be
considered
when
establishing
guidelines
product
shelf
life
optimal
treatment
outcomes.
Hematopoietic
stem
cell
transplantation
is
one
of
the
most
intricate
immune
therapies
used
for
patients
with
hematological
diseases
or
disorders.
In
addition
to
inherent
immunosuppression
from
their
primary
condition,
many
these
usually
receive
cytotoxic
chemotherapy,
radiation
therapy,
broad-spectrum
antibiotics,
experience
extended
nutritional
perturbations.
These
factors
collectively
lead
inflammation
and
disruption
gut
microbiota.
Additionally,
about
40–60%
undergoing
fully
HLA-matched
allogeneic
are
expected
develop
acute
graft-versus-host
disease
(aGVHD),
even
prophylactic
measures
such
as
calcineurin
inhibitors,
methotrexate/mycophenolate,
post-transplant
cyclophosphamide
treatment.
Recent
research
has
elucidated
complex
interplay
between
effectors
in
gastrointestinal
tract
microbial
populations
within
a
proinflammatory
peri-transplant
environment,
revealing
its
significant
effect
on
survival
complications
aGVHD.
This
review
will
explore
relationship
dysbiosis
during
mechanisms
that
can
help
clarify
link
microbiota
risk
GVHD,
along
emerging
therapeutic
strategies
aimed
at
addressing
hematopoietic
transplantation.
